Pfizer Files 8K - Other Events

Pfizer Inc. ( PFE ) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on April 28, 2014.

As described in Item 7.01 above, on April 28, 2014, the Company issued the Announcement disclosing, among other things, that (a) the Company previously submitted a preliminary, non-binding indication of interest to the Board of Directors of AstraZeneca regarding a possible merger transaction with AstraZeneca; (b) after limited high-level discussions regarding the Proposal, AstraZeneca declined to pursue negotiations, the discussions were discontinued on January 14, 2014 and the Company then ceased to consider the possible transaction; (c) in light of recent market developments, the Company contacted AstraZeneca on April 26, 2014 seeking to renew discussions, but AstraZeneca again declined to engage; and (d) the Company is currently considering its options with respect to AstraZeneca. A copy of the Announcement is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

The full text of this SEC filing can be retrieved at: d716893d8k.htm

Any exhibits and associated documents for this SEC filing can be retrieved at: 78003/000119312514161303/0001193125-14-161303-index.htm

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

Access Investor Kit for Pfizer Inc.


Subscribe to WSJ:

  (END) Dow Jones Newswires
  Copyright (c) 2014 Dow Jones & Company, Inc.